Sydney Lupkin
Stories
-
Widespread firings start at federal health agencies including many in leadership
Staffers began receiving termination notices this morning as part of a major restructuring at HHS. Some senior leadership are on their way out too.
-
Could legal weed make you sick? Here's how California tries to keep it safe
With no help from the federal government, states are trying to regulate recreational marijuana. California's Department of Cannabis Control works to keep contaminants out of joints, vapes and edibles.
-
Patients scramble as cheaper obesity drug alternatives disappear
Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That's left many patients wondering what to do next.
-
Production of cheaper alternatives to name brand obesity drugs will stop on Wednesday
Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.
-
Consumers can buy Zepbound direct from the drugmaker if they'll pay out of pocket
Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.
-
A website sold patients obesity drugs at affordable rates. Now they're paying the price
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
-
How safe is your weed? Patchy regulations may leave contaminants in the weed supply
Millions of Americans use cannabis and would like to think the products they buy are safe. But regulation is state by state and full of holes. NPR's new series digs into the risks and solutions.
-
The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.
-
RFK Jr. plans to keep a financial stake in lawsuits against the drugmaker Merck
RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, according to new filings with the Office of Government Ethics.
-
Medicare targets 15 more drugs for price negotiations -- including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
